FAQ
Frequently asked questions
Straight answers, grounded in the cited literature — no dosing instructions, no sourcing advice.
What does retatrutide do?
Retatrutide activates three hormone receptors at once — GIP, GLP-1 and glucagon — which suppresses appetite, improves glucose-dependent insulin release, and increases energy expenditure. In Phase 2 trials, the 12 mg dose produced a mean body-weight change of -24.2% at 48 weeks versus -2.1% with placebo [4].
How does retatrutide work?
It is a single 39-amino-acid molecule engineered to bind and activate the GIP, GLP-1 and glucagon receptors simultaneously, combining incretin-driven appetite suppression with glucagon-driven energy expenditure and lipid mobilization [1][2].
How to reconstitute retatrutide?
This site does not provide reconstitution, dosing, or preparation instructions for any compound — it is a research-literature digest, not an instructional or vendor resource. Retatrutide remains an investigational drug studied only under clinical-trial conditions [1].
Is retatrutide FDA approved?
No. As of 2026, retatrutide is investigational and in Phase 3 trials; it has not been approved by the FDA or any regulatory agency [1].
What is tirzepatide?
Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors. It was first FDA-approved in May 2022 for type 2 diabetes, with a later approval for chronic weight management [9].
How does tirzepatide work?
By engaging both the GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake [9].
What does tirzepatide do in the body?
It lowers blood glucose and drives significant weight loss; in a 72-week head-to-head trial it produced a -20.2% mean body-weight change versus -13.7% with semaglutide [8].
What is tirzepatide used for?
It is FDA-approved for type 2 diabetes and for chronic weight management in adults with obesity or overweight plus a weight-related condition [9]. Weight-loss dosing for people without diabetes was, per one clinical reference chapter, initially an off-label use before its obesity approval [9].
What does BPC-157 do in the body?
In animal studies, BPC-157 is described as a cytoprotective peptide most consistently linked to promoting angiogenesis — new blood vessel formation — through VEGFR2 receptor signaling [16]. Human evidence remains extremely limited [14].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone. It is a synthetic 15-amino-acid peptide derived from a fragment of a human gastric-juice protein, and its proposed mechanisms involve blood-vessel growth and tissue-repair signaling pathways, not the growth-hormone axis.
Does BPC-157 work immediately?
There is no controlled human evidence establishing an onset timeline. Community reports describe changes over one to three weeks, but these are anecdotal, not clinical evidence, and are not backed by controlled trials.
Does BPC-157 damage the liver?
Published human safety data are too limited to answer this directly — one small IV safety pilot in two adults found no measurable changes in hepatic biomarkers [13], but a 2025 narrative review concludes rigorous, large-scale human trials are lacking overall [14].
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), built on the first 29 residues of human GRF with four stabilizing substitutions. It comes in a long-acting "DAC" form and a short-acting "no-DAC" form [18].
What does CJC-1295 do?
It binds the GHRH receptor on the pituitary gland, stimulating the body's own pulsatile release of growth hormone and, downstream, IGF-1. In one human trial, single doses raised mean GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9-11 days [21].
Is CJC-1295 safe?
It is not approved for human use, and published human evidence is limited to small, short-term pharmacology studies [18][21]. Documented and theoretical safety concerns include fluid retention, effects on insulin sensitivity, and immunogenicity flagged in 2024 FDA committee materials [18].
How much CJC-1295 should I take?
This site does not provide dosing guidance for any compound. CJC-1295 has no established human therapeutic dose — it is sold only as a research chemical, and no clinical dosing standard exists outside the small pharmacology studies conducted to date [18].